Searchable abstracts of presentations at key conferences in endocrinology

ea0032p928 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Thyroid cancer in patients with acromegaly

Balcere Inga , Peculis Raitis , Klovins Janis , Pirags Valdis

Generously supported by IPSEN)-->It is known that acromegaly is associated with increased risk of benign and malignant tumours. Previous studies show the prevalence of nodular thyroid disease in 40–70% of patients with acromegaly, and a 5–7% prevalence of thyroid cancer in these patients, which is higher compared to the general population.Latvian Cancer Register data show an incidence of thyroid cance...

ea0016p341 | Endocrine tumours | ECE2008

Association of genetic variants of somatostatin receptor 5 with acromegaly

Klovins Janis , Kapa Ivo , Balcere Inga , Ciganova Darja , Nikitina-Zake Liene , Schioth Helgi , Pirags Valdis

Full gene coding sequence of somatostatin receptor 5 and 2000 bp of upstream region was estimated using direct sequencing in 28 patients with acromegaly and 97 controls. Total 19 polymorphisms were identified (SNP1-19) and possible haplotypes were reconstructed. From all polymorphisms found silent substitution SNP15 was significantly associated with acromegaly as compared with control group (P=0.005). Another substitution SNP17 involves the amino acid change from prolin...

ea0049ep931 | Pituitary - Basic | ECE2017

Whole exome sequencing of two non-secreting pituitary adenoma tumors from the same patient

Rovite Vita , Peculis Raitis , Balcere Inga , Stukens Janis , Konrade Ilze , Valtere Andra , Nazarovs Jurijs , Caune Olivija , Pirags Valdis , Klovins Janis

Pituitary adenomas (PA) are benign tumors that develop in pituitary gland. Hormone secreting PA can cause overproduction of pituitary hormones leading to different systemic endocrine disorders (acromegaly, Cushing’s disease and others). Non-secreting PA can promote headaches (stretching of the dural sheath) and visual field defects (chiasma compression). We managed to obtain resected tumor samples from the patient having non-secreting PA, first tumor was resected in 2010,...

ea0073pep3.7 | Presented ePosters 3: Pituitary and Neuroendocrinology | ECE2021

Transcriptome alteration landscape of pituitary neuroendocrine tumour tissue

Saksis Rihards , Megnis Kaspars , Peculis Raitis , Niedra Helvijs , Balcere Inga , Konrade Ilze , Steina Liva , Pirags Valdis , Rovite Vita

Pituitary neuroendocrine tumors (PitNETs) are non-metastatic neoplasms of the pituitary that may overproduce hormones leading to systemic disorders or tumor mass effects causing headache, vertigo, or visual impairment. The overall estimated clinical prevalence of PitNETs is 1 in 400 to 1 in 1000 people. Although the pathogenesis of PitNETs has been extensively studied the molecular factors underlying tumorigenesis, remission, and therapy response of PitNETs are still unclear. ...

ea0063p52 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Exome analysis of pituitary adenoma tissue derived cell cultures

Rovite Vita , Peculis Raitis , Mandrika Ilona , Petrovska Ramona , Megnis Kaspars , Balcere Inga , Konrade Ilze , Stukens Janis , Breiksa Austra , Nazarovs Jurijs , Pirags Valdis , Klovins Janis

Introduction: Pituitary adenomas (PA) are tumours of the anterior pituitary. Despite the benign nature these neoplasms cause increased mortality and morbidity. Clinically relevant PAs affect around 0.1% of population during their lifetime. Currently, there is no human PA cell culture models. Tissue cultures derived from PA surgery materials depending on harvesting conditions can form free floating aggregates called pituispheres (PS) or adherent mesenchymal stromal cells (MSC)....

ea0035p912 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Efficacy and safety of lanreotide autogel (LAN-ATG) 120 mg at extended dosing intervals (EDIs) in acromegalic patients biochemically controlled with octreotide LAR (OCT-LAR) 10 or 20 mg: The LEAD study

van der Lelij Art-Jan , Pronin Vyatcheslav , Balcere Inga , Lee Moon-Kyu , Rozhinskaya Liudmila , Bronstein Marcello , Gadelha Monica , Maisonobe Pascal , Sert Caroline

Introduction: EDIs with LAN-ATG therapy may help improve the burden associated with long-term acromegaly management. The LEAD study evaluated the efficacy and safety of this approach by switching from OCT-LAR conventional dosing to LAN-ATG EDI.Methods: LEAD was a multinational, multicentre, open-label, non-comparative study. Acromegalic patients with normal IGF1 after OCT-LAR 10 or 20 mg injections every 4 weeks for ≧6 months were switched to LAN-...

ea0063p726 | Pituitary and Neuroendocrinology 2 | ECE2019

Detection of pituitary adenoma specific circulating tumour DNA using semiconductor sequencing

Pečulis Raitis , Megnis Kaspars , Rovīte Vita , Laksa Pola , Niedra Helvijs , Balcere Inga , Nazarovs Jurijs , Stukēns Jānis , Konrāde Ilze , Pīrāgs Valdis , Klovinš Jānis

Objective: The most common type of pituitary diseases are pituitary adenomas (PA) of different origin. Although non-metastasizing, they still cause increased mortality and morbidity. Clinically significant PAs affect around 0.1% of population during lifetime. Circulating cell free DNA (ccfDNA) is approximately 165 bp long DNA fragments which are released in bloodstream upon cell death. ccfDNA has been used to investigate presence and properties of various cancers. Data on ccfD...